Intrathecal administration of thrombin inhibitor ameliorates cerebral vasospasm. Use of a drug delivery system releasing hirudin.
The role of thrombin as a spasmogen after subarachnoid hemorrhage was evaluated using the intrathecally administered thrombin inhibitor hirudin, released from a drug delivery system (DDS) based on collagen in a canine vasospasm model. The DDS was implanted into the cisterna magna with autologous blood in the hirudin-treated group. The reduction in the angiographical diameter of the basilar artery was only 19% in the hirudin-treated group on day 7, showing a significant difference between hirudin-treated and nontreated groups (p < 0.01). These results suggest that thrombin is an important cause of vasospasm. The collagen DDS has great potential for treatment in the cerebrospinal fluid milieu.
Kudo
A
A
Department of Neurosurgery, Iwate Medical University School of Medicine, Morioka, Japan.
Suzuki
M
M
Kubo
Y
Y
Watanabe
M
M
Yoshida
K
K
Doi
M
M
Kuroda
K
K
Ogawa
A
A
D000818:Animals; D000991:Antithrombins / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics*; D001488:Basilar Artery / Q000187:drug effects / Q000473:pathology; D002533:Cerebral Angiography; D002946:Cisterna Magna; D003094:Collagen; D004285:Dogs; D016503:Drug Delivery Systems / Q000379:methods*; D004343:Drug Implants; D005260:Female; D006629:Hirudins / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics*; D007278:Injections, Spinal; D008297:Male; D013345:Subarachnoid Hemorrhage / Q000188:drug therapy / Q000473:pathology; D013346:Subarachnoid Space / Q000473:pathology; D020301:Vasospasm, Intracranial / Q000188:drug therapy* / Q000473:pathology
D000991:Antithrombins; D004343:Drug Implants; D006629:Hirudins; D003094:Collagen